InMode Ltd.
INMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeInMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency. The $852.2M market capitalization puts INMD squarely in small-cap range for its industry. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Market Cap
$852.2M
Beta
1.86
P/E (TTM)
12.24
P/E (Fwd)
10.79
EPS (TTM)
$1.21
EPS (Fwd)
$1.37
ROE
12.3%
ROA
6.2%
Cash
$501.1M
Total Debt
$4.5M
Free CF
$47.4M
52W Change
-0.7%
Annual Financials
Cash vs Debt
Where INMD stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, INMD finished 3.41% above its 150-day moving average ($14.35) and 3.41% above its 200-day moving average ($14.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INMD overbought or oversold?
At the August 28, 2026 close, INMD's RSI(14) was 28.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $501.1M in cash comfortably exceeding the $4.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $47.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 12.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has pulled back from $454.3M (2022) to $370.5M (2025), a 18% decline worth watching.
With a beta above 1.5, INMD tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing INMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.